<DOC>
	<DOCNO>NCT02505217</DOCNO>
	<brief_summary>Treatment patient heart attack drug prevent formation blood clot show reduce patient 's risk subsequent cardiovascular event heart attack , stroke , death . Because new drug increase treatment option , development test guide treatment improve treatment selection reduce risk cardiovascular event well bleed . This study design ass value new test . It prospective study enroll patient heart attack . Blood take hospitalization heart attack ( 1 day heart attack ) second time 6 month later ambulatory clinical visit . Investigators perform biochemical test blood assess likelihood make blood clot . One tablespoon blood take time . Taking amount blood pose risk participant . Investigators ask participant whether bleed cardiovascular event initial evaluation , ambulatory follow-up 6 month , telephone interview 1 year enrollment . During 1 year participation , investigator review medical record record information manner protect identity participant . We hypothesize biochemical test result similar baseline 6 month follow-up biochemical test identify patient great risk cardiovascular event bleed . Treatment participant alter participation study .</brief_summary>
	<brief_title>Novel Biomarkers Thrombotic Risk</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Myocardial infarction demonstrate elevated marker cardiac injury ( troponin I ( TNI ) creatine kinase ( CK ) MB fraction ) presence coronary artery disease demonstrate cardiac catheterization perfusion image Treatment long term anticoagulant active infection malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>platelet reactivity , thrombin generation</keyword>
</DOC>